Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alglucosidase alfa in Chinese Late Onset Pompe Disease
NCT04676373Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- Jul 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoints: Six-minute walk test at 12 months, Forced Vital Capacity at 12 months and 1 more. Started Mar 2021; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT04676373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676373.